New oral anti-coagulants

There are currently 3 new oral anti-coagulant drugs or NOACs. There drugs are licenced for the treatment of atrial fibrillation.
There are pros and cons with regards to their use:

Pros:    Simple dosing regimen (once or twice a day, fixed dose)
            No interaction with foods or alcohol
            Limited number of interactions with other medications
            Rapid onset of anti-coagulant action
            No need for monitoring with blood tests
            Reduced risk of intracranial haemorrhage
            More effective than warfarin in reducing stroke risk (dabigatran)
            Reduced all cause mortality (apixaban)

Cons:    Cost (approximately £1.50 - 2.00 per tablet)
            Lack of experience with patients who bleed whilst taking the medication
            Lack of anti-coagulant effect if doses are missed